FDA clears zenocutuzumab-zbco under accelerated pathway for two tumor types
The agency's accelerated approval covers both non-small cell lung cancer and pancreatic adenocarcinoma, according to an FDA posting.
The FDA recorded an accelerated approval for zenocutuzumab-zbco on December 4, 2024, covering two indications at once. The approval applied to non-small cell lung cancer and pancreatic adenocarcinoma.1
The document available does not include further detail on the specific patient population, biomarker requirements, dosing, or the clinical trial data that supported the approval. It also does not specify the confirmatory trial requirements typical of accelerated approvals, nor does it name the manufacturer or sponsor of the drug.
Readers seeking fuller context on the approval, including trial results, prescribing information, or postmarketing commitments, would need to consult additional FDA records or the drug's labeling, as the source provided here is limited to the bare fact of the accelerated approval and its date.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.